التفاصيل البيبلوغرافية
| العنوان: |
Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses |
| المؤلفون: |
Florez, Helena, Hernández Rodríguez, José, Carrasco Jordan, Josep Lluís, Prieto González, Sergio, Muxí Pradas, África, Filella Pla, Xavier, Ruiz-Gaspa, Silvia, Gomez Puerta, José A., Cid Xutglà, M. Cinta, Espinosa Garriga, Gerard, Monegal Brancós, Ana, Guañabens Gay, Núria, Peris Bernal, Pilar |
| المصدر: |
Articles publicats en revistes (Fonaments Clínics) |
| بيانات النشر: |
BMJ Publishing Group |
| سنة النشر: |
2020 |
| المجموعة: |
Dipòsit Digital de la Universitat de Barcelona |
| مصطلحات موضوعية: |
Osteoporosi, Fractures, Densitat mineral òssia, Glucocorticoides, Osteoporosis, Bone density, Glucocorticoids |
| الوصف: |
Objective: The aim of this study was to identify the risk factors associated with fragility fracture (FF) development in glucocorticoid (GC)-treated patients. Methods: 127 patients (aged 62±18 years, 63% women) on GC-treatment (mean dose 14.5±14.1 mg/day and duration 47.7±69 months) were included. The clinical data collected included bone metabolism study (including gonadal axis), GC-treatment, disease activity, dual-energy X-ray absorptiometry analysis (evaluating densitometric osteoporosis (OP) and trabecular bone score (TBS) degraded microarchitecture values (DMA)), X-ray (assessing vertebral fractures (VF)), FRAX risk (GC-adjusted) and previous FF. Results: 17% of the patients had VF, 28% FF (VF and/or non-VF), 29% OP and 52% DMA. Patients with VF received more GC boluses (57.1% vs 29.5%, p=0.03), were older (68±13 vs 60±19 years, p=0.02), postmenopausal (100% vs 67%, p=0.02), had low testosterone levels (57% vs 11%, p=0.02), lower TBS values (1.119±0.03 vs 1.237±0.013, p<0.001) and higher FRAX risk (17.2±16 vs 9.3±7.6, p=0.003). Patients with FF showed higher accumulated GC doses (16.6±18.4 vs 11.1±12.9 g, p=0.046). On multivariate analysis, hypogonadism (OR 12.38; 95% CI 1.85 to >100, p=0.01) and having received GC boluses (OR 3.45; 95% CI 1.04 to 12.15, p=0.01) were the main factors related to VF. Hypogonadism (OR 7.03; 95% CI 1.47 to 38.37, p=0.01) and FRAX >20 (OR 7.08; 95% CI 1.28 to 53.71, p=0.02) were factors related to FF. Conclusion: Hypogonadism is the principal risk factor for developing fractures in GC-treated men and women, whereas receiving GC boluses is a major factor for VF. These results indicate the importance of evaluating the gonadal axis in these patients. |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
8 p.; application/pdf |
| اللغة: |
English |
| تدمد: |
2056-5933 |
| Relation: |
Reproducció del document publicat a: https://doi.org/10.1136/rmdopen-2020-001355; RMD Open, 2020, vol. 6, num. 2, p. e001355; https://doi.org/10.1136/rmdopen-2020-001355; http://hdl.handle.net/2445/174095; 707200 |
| الاتاحة: |
http://hdl.handle.net/2445/174095 |
| Rights: |
cc-by-nc (c) Florez et al., 2020 ; http://creativecommons.org/licenses/by-nc-nd/3.0/es ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: |
edsbas.62B9D046 |
| قاعدة البيانات: |
BASE |
Full Text Finder